Optimer Pharmaceuticals, Inc. Explores Collaborative Opportunities with C&O Pharmaceutical Technology

SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and C&O Pharmaceutical Technology (Holdings) Limited (Singapore Exchange Securities Trading: COPT) announced today that they have signed a non-binding Memorandum of Understanding (MOU) for the exploration of potential business collaborations in the U.S. and China. Under this MOU, the companies intend to jointly explore possible areas of cooperation, including sharing information on pre-clinical and clinical studies, screening and synthesizing new compounds, transferring technology, and licensing product candidates.